KineScience is a South Korea-based biotech company developing first-in-class peptide therapeutics targeting immune and neuroinflammatory pathways. Leveraging our proprietary cytokine ERDR1, we are advancing innovative treatments for CIDP, Alzheimer’s disease and other CNS disorders.

- KINE-101 has completed a Phase 1b/2a clinical study in CIDP patients successfully without nil issues. (S. KOR)

- KINE-101 has completed a Phase 1 study in the US demonstrating a good safety & tolerability profile.

- KINE-501 has shown preclinical proof-of-concept in AD animal model.